<DOC>
	<DOCNO>NCT01282463</DOCNO>
	<brief_summary>This multicenter trial enroll participant metastatic transitional cell carcinoma bladder , urethra , ureter , renal pelvis disease progression first-line platinum-based chemotherapy regimen . Participants enrol 1 3 treatment arm : docetaxel ; docetaxel ramucirumab ; docetaxel IMC-18F1 .</brief_summary>
	<brief_title>Study Ramucirumab IMC-18F1 With Docetaxel Docetaxel Alone Second-Line Therapy Participants With Bladder , Urethra , Ureter , Renal Pelvis Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Ramucirumab</mesh_term>
	<criteria>Histologically cytologically confirm transitional cell carcinoma bladder , urethra , ureter , renal pelvis Locally advance metastatic unresectable transitional cell carcinoma bladder , urethra , ureter , renal pelvis Had treatment platinumcontaining regimen Disease progression within 12 month receive last dose platinum contain regimen neoadjuvant adjuvant setting , and/or disease progression platinumcontaining regimen within 12 month last dose therapy locally advance metastatic setting Has measurable nonmeasurable disease Life expectancy ≥ 3 month Received 2 prior systemic chemotherapy regimen set Has Eastern Cooperative Oncology Group ( ECOG ) performance status 01 Has adequate hematologic , coagulation , hepatic renal function Does : cirrhosis level ChildPugh B ( bad ) cirrhosis ( degree ) history hepatic encephalopathy ascites result cirrhosis require ongoing treatment diuretic and/or paracentesis If female , surgically sterile , postmenopausal , compliant highly effective contraceptive method 12 week treatment period If male , patient surgically sterile compliant contraceptive regimen 12 week treatment period Received one prior systemic treatment regimen metastatic disease Received prior systemic taxane therapy ( except prior paclitaxel therapy ) Transitional Cell Carcinoma bladder , urethra , ureter , renal pelvis setting ( neoadjuvant , adjuvant , metastatic ) . Prior intravesical taxane therapy allow Has receive one prior antiangiogenic agent Transitional Cell Carcinoma bladder , urethra , ureter , renal pelvis Has receive radiation therapy within 4 week prior randomization Has history uncontrolled hereditary acquire bleed thrombotic disorder Has experience Grade ≥ 3 bleed event ( eg , via gastric ulcer , gastric varix , gross hematuria ) within 3 month prior randomization Has uncontrolled intercurrent illness include , limited symptomatic anemia , uncontrolled hypertension , symptomatic congestive heart failure , unstable angina pectoris , symptomatic poorly control cardiac arrhythmia , psychiatric illness/social situation , serious uncontrolled medical disorder Has experience arterial thrombotic thromboembolic event , include limited myocardial infarction , transient ischemic attack cerebrovascular accident , within 6 month prior randomization Has know brain metastasis , uncontrolled spinal cord compression , leptomeningeal disease Has ongoing active infection require parenteral antibiotic , antifungal , antiviral therapy Has know human immunodeficiency virus infection acquire immunodeficiency syndrome Has receive prior autologous allogeneic organ tissue transplantation Received chemotherapy within 21 day prior randomization ; and/or currently enrol , discontinue within 21 day prior randomization , clinical trial involve investigational product nonapproved use drug device ( study drug [ ] use study ) , concurrently enrol type medical research judge scientifically medically compatible study ; and/or treat antiangiogenic therapy within 28 day prior randomization Has undergone major surgery within 28 day prior randomization , subcutaneous venous access device placement within 7 day prior randomization Has serious nonhealing wound , ulcer , bone fracture within 28 day prior randomization Has elective plan major surgery perform course trial Is pregnant lactating Has concurrent active malignancy adequately treat nonmelanomatous skin cancer , curatively treated cervical carcinoma insitu , noninvasive carcinoma insitu neoplasm , prostate cancer undetectable prostate specific antigen ( PSA ) current treatment hormone therapy Has acute/subacute bowel obstruction history chronic diarrhea require ongoing medical intervention History gastrointestinal perforation and/or fistula within 6 month prior randomization Has active diverticulitis Known hypersensitivity docetaxel drug formulate polysorbate 80 Known hypersensitivity agent similar biologic composition ramucirumab DP , IMC18F1 , agent specifically target VEGF</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Carcinoma , Renal Cell</keyword>
</DOC>